By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events